Victoza liraglutide: Extension study data

In a 26-week extension of an open-label, international Phase III trial in 658 patients inadequately controlled with metformin, 1.2 and 1.8 mg once-daily subcutaneous Victoza led to

Read the full 273 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE